Abstract

Repositioning leptin as a therapy for Alzheimer\'s disease

Author(s): Jane M Johnston, Steven J Greco, Ashkan Hamzelou, J Wesson Ashford and Nikolaos Tezapsidis

The data from the initial clinical trials utilizing recombinant human leptin as an obesity therapy were published in 1998. Since then, numerous studies have been described which address dosage, safety and efficacy of leptin replacement for a variety of disorders with diverse patient groups, including pediatric and adult subjects. We review the current clinical trial data, demonstrate that leptin administration is safe for long term use in humans, and summarize reported cognitive benefits. The functions of leptin in neuroprotection and cognition have been largely overlooked. Accumulating data suggest a very significant application of leptin may be a therapy for Alzheimer’s disease.